Target ALS

11/06/2025

New funding opportunity: Target ALS is accepting applications for Basic Biology Consortia focused on understanding the fundamental biology of genetic and sporadic forms of ALS to help uncover the next wave of therapeutic targets.

We are seeking applications from multidisciplinary groups with novel and innovative methods in convergent and complementary multi-omic approaches, and applications of artificial intelligence and machine learning.

Learn more and apply today: https://ow.ly/6NKm50XnzpJ

11/06/2025

When Raquel Pozzani’s father, Valdir, was diagnosed with , life as she knew it changed overnight. Once an active cyclist, he quickly became bedridden, a transformation that shattered the family’s sense of normalcy but revealed extraordinary strength, love, and faith.

From small victories, like Valdir insisting on attending family celebrations, to the support of friends, former colleagues, and the broader ALS community, the Pozzanis have found beauty amid heartbreak. Now, Raquel is determined to turn that pain into purpose, helping connect Target ALS with researchers in Brazil to advance global collaboration and progress.

This , we honor the resilience of families like Raquel’s, whose love and perseverance remind us what’s at stake, and why our work must continue.

Read their powerful story: https://www.targetals.org/2025/10/16/finding-strength-courage-and-hope-raquel-pozzanis-family-journey-with-als/

11/04/2025

What a finish! 🏁

Team Target ALS crossed the finish line this past weekend at the 2025 TCS New York City Marathon, united by one goal: to advance ALS research.

Together, Lori, Alison, Alexander, Susan, and Andrew have raised $29,431 (and counting!), beating our $25,000 goal to accelerate the discovery of effective treatments for .
Every stride brought us closer to a future where Everyone Lives.

Support team Target ALS at: https://ow.ly/PVU250XmS4q

11/03/2025

For years, Howard Levine’s work focused on advancing digital biomarkers: tools that could transform how ALS is detected and monitored through speech, movement, and at-home data collection. But in July 2025, his work suddenly became personal.

When his mother-in-law was diagnosed with , Howard found himself seeing the disease from both sides, as a researcher and as a caregiver. That dual perspective reshaped his sense of urgency, deepened his empathy, and reinforced the power of bridging science with lived experience.
This , we honor the millions like Howard who carry both the weight of discovery and the weight of love.

Read his story and learn how personal experience is fueling progress in ALS research: https://www.targetals.org/2025/10/15/from-digital-biomarkers-to-personal-loss-howard-levines-journey-with-als/

For years, Howard Levine’s professional life centered on exploring how digital biomarkers could change the way we detect and monitor ALS. Then ALS touched his personal life.

10/31/2025

Bold ideas need strong support.

Through the Target ALS In Vivo Target Validation Program, we’re supporting researchers like Dr. Sarah Knutson of ROME Therapeutics, who are pushing into new territory. Her team is developing LINE-1 inhibitors—a potential way to stop neuroinflammation before it starts.

This is what collaboration looks like in action: scientists, nonprofits, and biotech working together to accelerate the path to treatments.

🔗 Learn more about this groundbreaking work: https://www.targetals.org/2025/10/13/halting-neuroinflammation-at-the-source-dr-sarah-knutsons-work-on-line-1-inhibitors/

10/31/2025

When Susan Griffin laces up for the New York City Marathon, she’s running for someone who changed how she sees strength and joy.

Growing up, Susan watched her friend’s mom, Jan, live with ALS for more than 20 years. Despite the toll of the disease, Jan’s warmth never faded, and she filled every day with laughter, friendship, and love for her family.

“Even with such a hard diagnosis, she lived such a full and joyful life,” Susan shared. “Running through her favorite city, in her honor, makes this dream even more meaningful.”

This November, Susan will run 26.2 miles with Team Target ALS to honor Jan’s memory and to help accelerate research toward a future where no one has to endure what Jan did.

🏃‍♀️ Support Susan’s journey and help advance ALS research: https://ow.ly/Lks450XkJmX

10/30/2025

At its core, the Target ALS origin story is about people: the ones who lead, build, and believe.
It’s about a founder who saw possibilities where others saw limits, a family who turned love into purpose, and a community of researchers who transformed collaboration into breakthroughs.

In “Everyone Lives: Turning Vision Into Reality,” you hear from the people who have witnessed Dan’s journey and believe in his vision for the future. Michael Bloomberg speaks about Dan’s incredible leadership, Alisa Doctoroff talks about the hope and belief in a world where Everyone Lives, and scientists like Dr. Joe Lewcock share how research is moving from the lab to clinical trials because of Target ALS.

This is more than a film. It’s a testament to what can happen when humanity and science move forward together.

🎥 Watch the full film now: https://youtu.be/NxaslvNqjAw?si=YSgUsbcil5eaAqe9

10/29/2025

Tonight, the story behind a global movement comes to life.

At 7 PM ET, join us for the world premiere of Everyone Lives: Turning Vision Into Reality. The Target ALS origin story.

This is the story of how one man’s mission became unstoppable momentum, transforming how science is done, how hope is built, and how collaboration is accelerating the search for effective ALS treatments.

Don’t just watch it, be part of it.
This is where the next chapter begins.

🎬 Live on YouTube tonight at 7 PM ET
➡️ Watch here: https://youtu.be/NxaslvNqjAw?si=G7ABfPJPN5jzKsat

10/28/2025

Tomorrow, the story unfolds.

🎬 Everyone Lives: Turning Vision Into Reality — the Target ALS origin story premieres October 29 at 7 PM ET.

Don’t miss the live event.

➡️ RSVP now to secure your spot: https://ow.ly/sySk50XjpzG

10/27/2025

When Dan Doctoroff lost his father and uncle to ALS, both carrying the mutation, currently the most commonly known genetic cause of and (frontotemporal dementia), he understood the disease in a deeply personal way. That experience became the catalyst for founding Target ALS, built on the belief that collaboration and innovation could change the trajectory of ALS.

Years later, Dan himself was diagnosed with ALS, but he tested negative for the C9 mutation, underscoring just how complex and unpredictable the disease truly is. Yet it also deepened his resolve to accelerate research for all forms of ALS.

Today, Target ALS is funding and enabling some of the most ambitious C9 research to date, supporting scientists exploring next-generation antisense oligonucleotides (ASOs) that may correct harmful protein behavior, and CRISPR-Cas9 gene-editing technologies that could one day rewrite faulty genetic instructions at their source. Each advance brings us closer to understanding, and ultimately changing, what it means to be diagnosed with ALS.

Read the Doctoroffs’ powerful story and learn how Target ALS is advancing research to unlock the next generation of treatments: https://ow.ly/qFp050XiA0h

10/24/2025

For the third year in a row, Lori Berko is running the New York City Marathon in support of Target ALS, a cause that’s deeply personal to her.

Lori runs not just for the fight against , but for a person: our founder, Dan Doctoroff. After losing his father and uncle to ALS and his own diagnosis, Dan turned his personal battle into a mission to change the trajectory of this disease for everyone.

“Dan has always been a visionary leader, whether in public service, business, or philanthropy, but what he has done with Target ALS is truly extraordinary,” Lori shared. “Running for Target ALS is my way of honoring his courage and commitment, and supporting a community that urgently needs breakthroughs.”

🏃‍♀️ Support Lori’s fundraising as she runs toward a future where : https://ow.ly/hXzG50XhwL8